XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 16, 2023
Apr. 30, 2019
shares
Nov. 30, 2023
shares
Apr. 30, 2019
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
shares
Jun. 30, 2022
shares
Sep. 30, 2023
USD ($)
Apr. 30, 2022
Accounts Receivable, Allowance for Credit Loss         $ 114,882     $ 42,180  
MerchantProcessingFee         2.50%        
Accounts Receivable, after Allowance for Credit Loss, Current         $ 576,901     585,345  
Revenue, Remaining Performance Obligation, Amount         0        
Contract with Customer, Asset, after Allowance for Credit Loss, Total         0        
Cash, Uninsured Amount         0.9     $ 1.2  
Net Income (Loss) Attributable to Parent         (996,501) $ (3,956,062)      
Working Capital         $ (1,394,198)        
Reverse Stock Split [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio 45                
Customer Concentration Risk [Member] | Revenue Benchmark [Member]                  
Number of Major Customers         0        
cbdMD and directCBDonline Trademarks [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)         5 years        
Trademark Related to Hemp MD [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)         10 years        
Manufacturing Equipment [Member]                  
Property, Plant and Equipment, Useful Life (Year)         5 years        
Software [Member]                  
Property, Plant and Equipment, Useful Life (Year)         3 years        
Maximum [Member]                  
MerchantProcessingFee         5.00%        
Maximum [Member] | Reverse Stock Split [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio 50                
Minimum [Member] | Reverse Stock Split [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio 20                
Cure Based Development, Llc [Member] | Common Stock [Member]                  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares       338,889     271,405    
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)                 5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares) | shares     19,818 338,889          
Cure Based Development, Llc [Member] | Unregistered Common Stock [Member]                  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares   194,445   194,445          
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)   5 years   5 years          
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares) | shares           338,889